quantisnow
FeedTopReportsPricing
⌘K
Live feed
13:49:45·134d
INSIDERFiling
Klotho Neurosciences Inc. logo

SEC Form 4 filed by Director Mcgarity Jon

KLTO· Klotho Neurosciences Inc.
Health Care
Original source

Companies

  • KLTO
    Klotho Neurosciences Inc.
    Health Care

Related

  • SEC38d
    Klotho Neurosciences Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
  • SEC42d
    Klotho Neurosciences Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
  • PR42d
    Klotho Neurosciences Completes Rebranding to Greenland Mines Ltd and Change of Nasdaq Ticker Symbol to GRML
  • SEC44d
    Klotho Neurosciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Unregistered Sales of Equity Securities, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
  • PR45d
    Klotho Neurosciences Announces Rebranding to Greenland Mines Ltd and Change of Nasdaq Ticker Symbol to GRML Effective March 12, 2026
  • INSIDER48d
    Chief Financial Officer Leblanc Jeff was granted 2,500,000 shares, increasing direct ownership by 272% to 3,420,342 units (SEC Form 4)
  • INSIDER48d
    Director El-Dada Riad Hussein was granted 350,000 shares (SEC Form 4)
  • INSIDER48d
    Director Zentman Samuel M was granted 350,000 shares, increasing direct ownership by 48% to 1,086,440 units (SEC Form 4)
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022